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REVIEW
Abstract: Functional recovery, the goal of treatment, has long been overlooked in the
assessment of effectiveness of pharmacological treatments. However, with the recent shift in
paradigm, from syndromal–symptomatic recovery to functional recovery, there appears to be
a new interest in the definition and evaluation of functional recovery. Since functional recovery
lags symptomatic recovery, sometimes by months or years, the attainment of functional
recovery will be determined by both efficacy and long-term compliance. Quetiapine, due to
its efficacy in both mania and depression, and effect on cognition may lead to improved
functioning in patients with bipolar disorder.
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Introduction
We stand in time at an important juncture in approaches to assess treatment
effectiveness or outcomes in bipolar disorder. Almost all studies evaluating treatments
for mania, mixed episodes, mood instability, and depression have been tested in a
paradigm that focuses on the percentage of patients achieving reduction of total
symptomatology (symptomatic–syndromal recovery) at time of study entry by half
(response rate) or the time it takes to reach syndromal–symptomatic recovery, or, for
long-term studies, the duration of time that they were maintained without developing
a new affective episode or the percentage of patients who experienced a relapse or
recurrence after an index episode.
This focus is despite the DSM-IV TR necessitating functional impairment as a
condition sine qua non for the diagnosis of depressive, manic, or mixed episodes in
bipolar illness (DSM-IV). Functional recovery, in bipolar illness, may be described
as the return to a level of functioning that existed prior to the development of the
most recent episode (Tohen et al 2000) and may involve several domains such as
capacity to work, live independently, study, and engage in recreational activities
(Zarate et al 2000). Several studies over the past decade have made clear that there is
a disconnect between remission and response, between syndromal and symptomatic,
and between syndromal and functional recovery. This article focuses on the last, but
addresses the others, as each contrast is interrelated with the other.
Comparative function in bipolar disorder and
major depression
The recent report from the 2005 national comorbidity epidemiological study found
that bipolar disorder had the highest percentage of patients classified in the severely
ill group (83%) compared with 30% of patients with major depression and the next
highest group, obsessive compulsive disorder, at 50% (Kessler et al 2005). In a separate
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study, patients with bipolar disorder had twice the rate of
psychosocial impairment as major depressed subjects
(Hirschfeld 2005). Additionally, bipolar patients were
approximately twice as impaired in their sense of vitality,
and social and emotional role function as unipolar depressed
patients (Yatham et al 2004). Socio-occupational
dysfunction, in bipolar disorder, is positively correlated with
continued depressive symptomatology (Bauer et al 2001).
Bipolar patients spend nearly 50% of their time being
symptomatic, with a predominance of depressive symtoma-
tology both in bipolar I and II patients (Judd et al 2002),
which may explain the associated functional impairment.
Moreover they tend to experience prominent anergic
symptoms during their depressive episodes which may
further account for greater burden of illness (Bowden 2001).
Kessler et al also found that although the prevalence of major
depression in the workplace is twice that of bipolar disorder,
because of the greater persistence of symptoms bipolar
patients account for significantly more workdays lost
(Kessler et al 2005).
The symptomatic and functional impairment associated
with bipolar disorder negatively affects family care
providers. More than 90% of caregivers of bipolar family
members reported moderate or greater distress, with the
degree of burden predicting poor outcome at 7 and 15
months (Perlick et al 2001).
Relationship of syndromal to
functional improvement
It has been consistently demonstrated, in studies lasting up
to two and a half years (Dion et al 1989; Harrow et al 1990;
Tohen et al 1990; Zarate et al 2000; Nemeroff et al 2003),
that functional improvement lags syndromal improvement.
Additionally, a much smaller proportion of bipolar patients
reach functional recovery compared with those who attain
syndromal recovery. In one study, 30%–60% of patients,
continued to experience psychosocial dysfunction during
inter-episode intervals (MacQueen et al 2001). The
persistence of psychosocial impairment despite syndromal–
symptomatic recovery argues against the periodic nature of
bipolar illness characterized by affective episodes and
emphasizes the chronic nature of this illness.
In the aggregate, this consistent evidence of greater
difficulty in achieving functional recovery, and the longer
time to achieving it, has contributed to recent efforts to
incorporate measures of patient function and quality of life
in prospective clinical trials. Even the assessment of
remission as a primary efficacy measure, rather than a
response, may serve this purpose. Although remission is a
more stringent criterion to assess efficacy of a treatment
modality than response, in one recent placebo-controlled
study comparing quetiapine and lithium with placebo in
manic patients over a 12-week period of blinded treatment,
the magnitude of the advantage of both drugs over placebo
was larger for proportions remitted than for those simply
responsive (Bowden, Grunze, et al 2005). Whereas the
remission rate remained almost as high as the response rate
for the two active treatments, remission was notably lower
with placebo treatment than was response. This suggests
that response incorporates some partial and non-specific
improvement that is unlikely to lead to major recovery in
function or quality of life.
Efficacy vs effectiveness
The single focus on global symptomatic improvement in
studies of acute depression and mania, usually lasting 3–12
weeks, essentially meant that not only functional recovery
but also tolerability to treatment regimens was given almost
no attention. This approach was in part consequent to studies
of mania and depression being short term, and studies of
mania being conducted in hospitalized patient samples, and
acceptability of side-effects were quite secondary. With a
paradigm shift toward an illness-focused rather than an
episode-focused overall approach to treatment, the
acceptability of a treatment regimen began to receive more
attention. Acceptability of a medication regimen, particularly
long term, is an integral part of ease of administration and
tolerability. A treatment that must be taken, for example,
three times daily will be less acceptable than one that is
taken once daily (Mulleners et al 1998). A treatment that
has subjectively distressing side-effects will lead to high
rates of drop out (Vieta et al 2005). Such studies are both
more feasible and more important in longer-term trials. For
example, the sexual interest-impairing effects of selective
serotonin re-uptake inhibitors (SSRIs) may be borne by most
patients over a 6-week acute study while initially depressed,
but prove less acceptable over an indefinite period of use,
particularly with resolution of depressive symptomatology.
Although the high side-effect burden of lithium was well
known from its early use, the serious adverse effect on
outcomes from this has become especially apparent in long-
term studies published in the past 15 years. In a follow-up
of patients discharged from hospital taking lithium following
a manic episode, the mean duration of time that patientsNeuropsychiatric Disease and Treatment 2006:2(2) 151
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continued to take the drug was only 65 days (Johnson and
McFarland 1996). Simply put, a treatment may have limited
effectiveness, despite proven efficacy in clinical studies
Impact of function on
pharmacotherapy
Pharmacotherapy can affect functional status over time just
as aspects of daily function can impact pharmacotherapy,
both positively and negatively. A patient who does not obtain
adequate sleep will experience reduced benefits of
medications for bipolar disorder. Conversely, developing a
daily routine that includes reasonably early and sustained
sleep can augment benefits of drugs (Frank et al 2005).
Stimulants or other drugs of abuse–dependence, worry,
anxiety-provoking stressors, and medical illnesses are
among the many life events that can serve as acute and long-
term stressors, adversely affecting outcomes, by such
pathways as worsening insomnia or destabilizing mood
(Nemeroff et al 2003)
Potential for drugs to affect
function
For all classes of drugs, there is more inferential information
than experimental. And for each drug, side-effects will
dampen function, while beneficial effects may improve it.
Lithium
Lithium may well have the least potential to improve
function due to the large number of adverse effects,
particularly cognitive, many of which worsen with age and
duration of treatment. There is evidence that patients with
bipolar disorder have significant cognitive deficits, even
when asymptomatic (Atre-Vaidya et al 1998; van Gorp et
al 1998), which are closely related to psychosocial and
functional impairments. Moreover, lithium may lead to
induction of depressive symptomatology which may further
impair functionality (Bowden, Collins, et al 2005).
Conversely, mostly open studies compared with normative
data suggest that lithium may reduce suicidal behavior even
when not effective as a mood stabilizer (Tondo et al 2001).
Valproate
Valproate has a relatively broad spectrum of efficacy, and
some evidence of benefits on irritability not reported with
other mood stabilizers. Valproate may also positively affect
cognition, when used with both typical and atypical
antipsychotics, by causing a larger increase in prefrontal
cortical dopamine release via 5-HT-1A receptor activation
(Ichikawa et al 2005). Valproate, unlike lithium, does not
cause precipitation of depressive symptomatology in bipolar
patients and hence will not negatively impair psychosocial
functioning. With the exception of causing weight gain,
valproate does not have adverse effects that routinely
develop over time. In comparison randomized studies with
lithium, carbamazepine, and olanzapine, valproate has had
fewer adverse effects (Bowden et al 1994, 2000;Vasudev et
al 2000; Tohen et al 2002)
Lamotrigine
Lamotrigine has efficacy principally on depressive
components of bipolar disorder. Since depressive
components are more strongly associated with functional
impairment than are manic symptoms, it is plausible that on
an efficacy basis alone lamotrigine should contribute to
improving function. Lamotrigine also has a remarkably well
tolerated adverse effect profile which positively affects
effectiveness. The limitation of potential for hypersensitivity
syndrome is serious, but largely unrelated to issues of long-
term function.
Carbamazepine
This drug has a mixed adverse-effect profile that may appear
less conducive to good function than is actually the case. It
causes substantial psychomotor sedation, ataxia, blurred
vision, and impaired coordination in early dosing; however,
such symptoms often abate with continued use. Although,
like lamotrigine, it is associated with hypersensitivity
syndrome, this infrequent and early complication is unlikely
to affect function. However, carbamazepine has been little
studied in long-term trials, and the two principal recent trials
have shown it to be generally inferior to and less well
tolerated than lithium.
Antipsychotic drugs
Although there are class-effect adverse problems associated
with antipsychotics, it is more realistic to view the individual
atypical agents separately, and similarly the first generation
typical drugs as a group.
First-generation drugs
Although efficacy in mania is equivalent for these drugs,
there is substantial evidence that these antipsychotics may
precipitate depressive episodes with long-term usage, which
may affect functioning negatively. Moreover, these agents
have a range of side-effects that are generally lacking in allNeuropsychiatric Disease and Treatment 2006:2(2) 152
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atypical antipsychotics such as anticholinergic,
extrapyramidal, and histaminergic actions, which may also
interfere with tolerability and hence long-term adherence.
Olanzapine and clozapine
These two drugs appear to share more similar profiles than
do any other atypical antipsychotics, in part linked to their
common dibenzodiazepine structures. At therapeutic doses,
low-density lipoprotein levels increase, insulin resistance
occurs, glucose is consequently dysregulated, and obesity
is difficult to control with dosing or dietary strategies,
although some promising results have been observed with
concurrent use of appetite-suppressant drugs. Early
discontinuation rates have been relatively high for the two
drugs, in part consequent to such side-effects that are
associated with all of the medical consequences of the
metabolic syndrome (Lakka et al 2002)
Quetiapine
Quetiapine has a spectrum of efficacy that should contribute
toward improved functioning. It has established benefits
both for mania and depressive syndromes in patients with
bipolar I and II disorders, therefore potentially benefiting
both facets of the disorder (Bowden, Grunze, et al 2005).
Additionally, it has moderate sedative effects, which in doses
of around 100 mg at bedtime appear anecdotally to be useful
in the sleep disruption, not simply insomnia, which is
intrinsically common in bipolar disorder. The sedative
effects are dose dependent, and have been associated with
increased early discontinuation rates in studies. Moreover
quetiapine, in a randomized, blinded study (Velligan et al
2003), has been shown to improve cognition in patients with
schizophrenia. This cognitive-enhancing property of
quetiapine may positively affect psychosocial functioning
given the direct correlation of the two. In bipolar disorder,
quetiapine has not yet been studied in large-scale, long-
term, randomized, controlled studies, but studies in
schizophrenia suggest mild to moderate weight gain, and
substantially less affect on facets of the metabolic
syndrome.
Most major studies of quetiapine have included rating
scales to assess functional status and patient satisfaction. In
the 12-week study of acutely manic patients, 88% of patients
achieving response after 3 weeks of treatment continued to
show response, at 12 weeks, and had similarly maintained
rates of remission at the two time points.
Depressed bipolar I and II patients treated with
quetiapine for 8 weeks reported significant improvement
on a self-rated quality of life scale (Q-LES-Q) for both a
300 mg/day dose and a 600 mg/day dose of quetiapine.
Degree of improvement was equivalent for the two dosages,
as was degree of improvement on the MADRS (Calabrese
et al 2005). Unlike SSRIs, quetiapine at both doses was not
associated with sexual side-effects. These results indicate
that quality of life and patient satisfaction can be
meaningfully assessed in a relatively short 8-week study of
treatments for depression, and that significance levels are
essentially as high as seen for symptomatic change. Further,
they indicate that for quetiapine the combination of
symptomatic efficacy, breadth of effectiveness, adequate
tolerability, particularly in several areas that are functionally
impairing with other antipsychotic treatments for bipolar
disorder, and association of improved quality of life with
improved symptoms is indicative of the kind of profile of
benefit desirable for treating a multifaceted, lifelong disorder
such as bipolar disorder.
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